Registry Study for Optimal Management of Liver Failure in the Chinese Population (RESOLVE-C)

Status: Recruiting
Location: See all (14) locations...
Intervention Type: Procedure
Study Type: Observational
SUMMARY

Liver failure is the most severe form of liver damage caused by viral, alcoholic, drug-related and ischemia-reperfusion factors, often combined with extrahepatic organ damage, resulting in a high mortality rate. This study intends to construct a real-world case registry database of inpatients with liver failure based on an electronic clinical data collection system through a multicenter collaborative network to study the clinical characteristics, epidemiology of bacterial and fungal infections, the impact of sarcopenia on clinical prognosis, and optimization of treatment strategies such as antiviral and artificial liver in Chinese inpatients with liver failure. The cohort and experience generated from this study will be used as a support for a series of future studies to focus on clinical issues such as infection, end-stage liver disease combined with organ failure, and early warning of critically ill patients.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

⁃ Patients with a diagnosis consistent with liver failure and pre-liver failure:

• Extreme weakness with significant gastrointestinal symptoms such as anorexia, vomiting and abdominal distention;

• Elevated alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) with progressive jaundice (TBil≥85.5 μmol/L);

• Bleeding tendency with PTA ≤ 60% or INR ≥ 1.5.

Locations
Other Locations
China
Ankang Central Hospital
RECRUITING
Ankang
Xiangya Hospital of Central South University
NOT_YET_RECRUITING
Changsha
Hanzhong 3201 Hospital
NOT_YET_RECRUITING
Hanzhong
Qilu Hospital of Shandong University
NOT_YET_RECRUITING
Jinan
First Hospital of Lanzhou University
NOT_YET_RECRUITING
Lanzhou
Weinan Central Hospital
NOT_YET_RECRUITING
Weinan
Air Force Medical University Tangdu Hospital
NOT_YET_RECRUITING
Xi'an
First Affiliated Hospital of Xi'an Jiaotong University
RECRUITING
Xi'an
Shaanxi provincial people's hospital
NOT_YET_RECRUITING
Xi'an
The Second Affiliated Hospital of Xi'an Jiaotong University
RECRUITING
Xi'an
Xi 'an International Medical Center Hospital
NOT_YET_RECRUITING
Xi'an
Xianyang Central Hospital
RECRUITING
Xianyang
The Affiliated Hospital of Yan'an University
NOT_YET_RECRUITING
Yanan
General Hospital of Ningxia Medical University
NOT_YET_RECRUITING
Yinchuan
Contact Information
Primary
Yingli He, Pro.
heyingli2000@xjtu.edu.cn
0086-18991232863
Backup
Juan Li, M.D.
lijuan1996xx@163.com
0086-18209272726
Time Frame
Start Date: 2023-01-06
Estimated Completion Date: 2028-12-30
Participants
Target number of participants: 500
Treatments
ALF
acute liver failure
SALF
subacute liver failure
ACLF
acute-on-chronic liver failure
Related Therapeutic Areas
Sponsors
Leads: First Affiliated Hospital Xi'an Jiaotong University

This content was sourced from clinicaltrials.gov